ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 220 citations in OpenAlex.
- Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis.BMC anesthesiology · 2022Pooled it
- D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.Blood transfusion = Trasfusione del sangue · 2020Trial
- Effect of combination therapy with recombinant thrombomodulin and antithrombin on outcomes in patients with sepsis-induced disseminated intravascular coagulation in a surgical intensive care unit: a retrospective observational study.Journal of anesthesia · 2026Article
- Fulminant Thromboinflammatory Syndrome Following an Influenza-like Illness in an Adolescent: Clinical Insights from a Case Report.International journal of molecular sciences · 2026Article
- Immune-mediated acute thrombocytopenia within 30 minutes of first obinutuzumab infusion.Blood vessels, thrombosis & hemostasis · 2026Article
- Omsk Hemorrhagic Fever Virus and Powassan Virus Infections at Different Times After Immunization with the TBE Vaccine in In Vivo Experiments.International journal of molecular sciences · 2026Article
- Subcutaneous Thrombotic Vasculopathy with Features of Leukocytoclastic Vasculitis Following Intravenous Injection of Crushed Oxycodone and Methylphenidate Tablets: A Case Report with Literature Review.Journal of clinical medicine · 2026Article
- Deep vein thrombosis and coagulopathy following cyclone events: pathophysiology, risk factors, and prevention.Annals of medicine and surgery (2012) · 2026Review
- Revisiting the Concept of DIC: A Phenotype-guided Framework for Modern Hemostatic Medicine.Juntendo medical journal · 2026Review
- Uncovering distinct clinical phenotypes in disseminated intravascular coagulation through machine learning-enabled cluster analysis.Frontiers in molecular biosciences · 2026Article
- Clinical characteristics of thrombocytopenia in tropical diseases and management in resource-limited settings.Research and practice in thrombosis and haemostasis · 2026Review
- Spontaneous intermuscular hematoma in mixed connective tissue disease: a case report.Frontiers in surgery · 2026Article
- Sepsis-induced coagulopathy: recent insights on the role and clinical application of neutrophil extracellular trap formation.Scientific reports · 2025Article
- Efficacy and safety of anticoagulant therapy in patients with sepsis: a meta-analysis of randomized controlled trials.Thrombosis journal · 2025Article
- Beyond Thrombopoiesis: The Immune Functions of Megakaryocytes in Bacterial Infections and Sepsis.International journal of molecular sciences · 2025Review
- The Differential Diagnosis of Thromobocytopenia.Deutsches Arzteblatt international · 2025Review
- Novel Insight into Dugong Mortality: First Report of SystemicAnimals : an open access journal from MDPI · 2025Article
- Coagulopathy as a Complication of Cardiopulmonary Arrest Following Balloon Valvuloplasty in a Dog.Veterinary medicine and science · 2025Article
- Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy.Journal of medicinal chemistry · 2025Article
- Maternal and Fetal Outcomes in Pregnant Women With Lung Cancer: A Population-Based Study on 9 Million Pregnancies and 40 Cases of Lung Cancer.BJOG : an international journal of obstetrics and gynaecology · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
Disseminated intravascular coagulation (DIC) is an acquired clinicobiological syndrome characterized by widespread activation of coagulation leading to fibrin deposition in the vasculature, organ dysfunction, consumption of clotting factors and platelets, and life-threatening hemorrhage. Disseminated intravascular coagulation is provoked by several underlying disorders (sepsis, cancer, trauma, and pregnancy complicated with eclampsia or other calamities). Treatment of the underlying disease and elimination of the trigger mechanism are the cornerstone therapeutic approaches. Therapeutic strategies specific for DIC aim to control activation of blood coagulation and bleeding risk. The clinical trials using DIC as entry criterion are limited. Large randomized, phase III clinical trials have investigated the efficacy of antithrombin (AT), activated protein C (APC), tissue factor pathway inhibitor (TFPI), and thrombomodulin (TM) in patients with sepsis, but the diagnosis of DIC was not part of the inclusion criteria. Treatment with APC reduced 28-day mortality of patients with severe sepsis, including patients retrospectively assigned to a subgroup with sepsis-associated DIC. Treatment with APC did not have any positive effects in other patient groups. The APC treatment increased the bleeding risk in patients with sepsis, which led to the withdrawal of this drug from the market. Treatment with AT failed to reduce 28-day mortality in patients with severe sepsis, but a retrospective subgroup analysis suggested possible efficacy in patients with DIC. Clinical studies with recombinant TFPI or TM have been carried out showing promising results. The efficacy and safety of other anticoagulants (ie, unfractionated heparin, low-molecular-weight heparin) or transfusion of platelet concentrates or clotting factor concentrates have not been objectively assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.